, and Caroline Foster d Purpose of review Adolescents living with HIV are the only age group with increasing HIV mortality at a time of global scaleup of access to antiretroviral therapy (ART). As a 'treat all' strategy is implemented worldwide, it is critically important to optimize retention and adherence for this vulnerable group.
INTRODUCTION
There are an estimated 1.8 million adolescents living with HIV (ALHIV) globally, 80% living in SubSaharan Africa (SSA) [1] . In recent years, older adolescents (15-19 years) are the only age group with increasing HIV mortality, at a time of massive scaleup of treatment programs, and when mortality is declining in all other age groups [2,3 && ]. High adolescent HIV mortality reflects critical gaps in the HIV care cascade, including low rates of retention in care, and complex challenges with adherence to antiretroviral therapy (ART) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The adolescent years (10-19 years) encompass significant physiological and psychosocial changes that confer particular vulnerability for adolescents living with either perinatally (PHIV) or behaviorally acquired HIV infection (BHIV) [4, 5, [16] [17] [18] . These changes continue to impact outcomes into young adulthood (20-24 years) [7, 10, [18] [19] [20] .
Failure to optimally diagnose, retain, and treat adolescents and young adults living with HIV (AYALHIV) has broad implications for the global epidemic. Viral suppression is critical to preventing onward transmission and reducing morbidity and mortality [21] [22] [23] [24] . The Joint United Nations Programme on HIV/AIDS '90-90-90 ' goal that 90% of persons living with HIV are diagnosed, 90% on treatment, and 90% virally suppressed to end the AIDS epidemic, cannot be achieved without a sustained and targeted effort to improve targets are yet to be met for adults in many HIC and remain an enormous challenge for AYALHIV [27] . The rise in HIV-associated mortality in adolescence is driven by the emerging cohort of long-term survivors of the PHIV epidemic who join the ever-increasing numbers of BHIV AYA, although robust data interpretation is frequently hampered by lack of disaggregation by both age and route of infection [3 && ]. Further complexity for data collection occurs during transition, with tracking of ALHIV into adult care by accurate linkage of national pediatric and adult surveillance systems proving challenging [ . Although transfer between pediatric and adult services has been highlighted as a particular barrier to retention, half of this cohort had disengaged from pediatric care prior to reenrolling in adult care, highlighting the complexity of disentangling the impact of service change from the multiple physical, psychosocial, and economic challenges during adolescence [33] . Linked data for 271 PHIV British youth tracked from pediatric to adult care showed a decline in CD4 counts prior to transfer; after transfer, counts continued to decline in black men, remained constant in white men and black women, and increased in white women [34 & ]. Age at transfer and moving hospital had no apparent impact, however, more recent calendar year was associated with better outcomes, potentially reflecting improvements in ART and/or transition over time. Transition typically occurs during late adolescence in Europe, often extending into young adulthood in the United States [33] . Populations vary by route of transmission; with predominantly PHIV in Europe and a larger proportion of BHIV in US cohorts. Comparison of transition outcomes by route of infection reviewed by Lam et al. [35] highlights the barriers faced, including the higher rates of accumulation of HIV-1-associated drug resistance mutations in PHIV compared with BHIV, resulting in more complex ART, impacting on adherence [36] .The paucity of data on acquired drug resistance in ALHIV is highlighted. In the United Kingdom, 291 of 644 adolescents transferring to adult care had resistance
KEY POINTS
Adolescence is the only age group where HIV associated mortality continues to rise. AYALHIV experience poorer rates of retention in care and adherence to ART compared with adults, because of multiple psychosocial challenges that complicate HIV care at this developmental stage.
There are remarkably few studies of targeted interventions to improve retention in care and adherence to ART or AYALHIV.
There is a need for data, disaggregated by age and route of infection on outcomes and targeted interventions for retention in HIV care of for AYALHIV that includes pregnant adolescents, and those from key populations groups, both in HIC and LMIC.
Interventions are needed which mitigate stigma and strengthen social support for AYALHIV to improve retention in care. data available; 82% with resistance to at least one drug class, 56% to at least two classes, and 12% triple-class resistance, reflecting the longterm consequence of poor pediatric viral suppression rates because of more limited ART options, unpalatable formulations, and dependency on parents/carers [37] . Small European cohorts have recently published posttransition data for predominantly PHIV youth. In Holland, virological failure increased posttransition [38] . In contrast, a very small Swedish cohort (n ¼ 23) reported posttransition viral suppression rates above 90%, comparable with adults [39] . However, HIC mortality data are emerging; 117 HIV-related deaths were reported in 60 900 American 15-24-year olds [3 && ,30] . A mortality audit of young UK adults with PHIV highlights the interplay of mental health diagnoses with poor adherence, leading to advanced disease [40] .
How do we improve retention in care and adherence to ART? Fortenberry et al. [41 && ] show how addressing the need for structural change in fragmented US services improves outcomes for AYAL-HIV. Through a coordinated program of crossagency collaboration, youth-friendly linkage to care, and community mobilization, more than 75% of almost 4000 youth linked to care, with nearly 90% retained [41 && ]. A US single-centre pilot intervention comparing a program of nontraditional HIV testing, motivational interviewing, and case management with standard of care for newly diagnosed youth (18-24 years) showed significantly higher rates of linkage to care (96 vs. 57%, P < 0.001) within a shorter time frame and improved adherence for the intervention group [42] . Strategies to improve reengagement after loss to follow-up (LTFU) from adult care through outreach coordinators, peer facilitators, and LTFU protocols have encouraging results but lack age-disaggregated data for AYA [43, 44] . The use of mobile phone technology to improve adherence in adolescents has shown promise in terms of feasibility and acceptability, although more modest efficacy, and is being evaluated further in the US 'weCare' program [45] [46] [47] . This US-based program targets MSM, ages 13-34 years, who are consumers of social media using Facebook, text messaging, and established global positioning system-based mobile applications as a platform for improving linkage and retention to care [47] . Outcome data are awaited for this group with typically very low retention rates. The unmet needs and lack of outcome data for young people in key population groups, including pregnant adolescents, those who inject drugs, transgender youth, sex workers, and AYA within the criminal justice system, requires urgent attention.
ADOLESCENTS AND YOUNG ADULTS HIV CARE IN LOW AND MIDDLE-INCOME COUNTRIES
HIV poses a significant threat to adolescents in SSA today and an important cause of adolescent mortality in this region, with an estimated 36 000 deaths per year [2, 16] . From 2000 to 2015, adolescent AIDSrelated deaths more than doubled in the 25 countries with 86% of the world's ALHIV [48] . Compared to their pediatric and adult counterparts in LMICas in HIC -AYALHIV have poorer retention in care, lower rates of virological suppression, and higher mortality [3 && ,49,50] . Adolescent disengagement from care presents a major challenge for global HIV programs. Only 20% of the world's ALHIV are on ART [48] . In South Africa, youth (15-24 years) have the lowest proportion on ART of any age group, with only an estimated 10% virally suppressed [51,52 & ]. In pooled data from global International Epidemiology Databases to Evaluate AIDS (IeDEA) cohorts including 115 549 children (0-19 years) enrolled in HIV care, 20.8% were LTFU before ART initiation, and adolescents had the lowest initiation rate (54.3%) [53] . In an analysis of East Africa IeDEA sites, older adolescents (15-19 years) experienced the highest rate of LTFU within 2 years (51%) and the lowest ART initiation rate (20%) [54] . [59, 60, 62, 71] , in addition to elements of the clinic [58, 60] and school environments [58, 60] . Emerging facilitators include strong social support networks, supported disclosure of HIV status to the child or close family members, family stability and support, and future orientation and self-sufficiency of adolescents [59] [60] [61] 63, 64 && ]. Efforts to improve retention of [72] [73] [74] . In Kenya, AFS were implemented at six clinics; training providers in adolescent care, monthly dedicated adolescent HIV clinics, integrating sexual and reproductive health, and establishing peer support programs [75] . Pre-ART LTFU decreased at AFS clinics, although not statistically significant, with no difference in LTFU or mortality between AFS and non-AFS clinics, and no impact on post-ART LTFU [75] . Another study in Kenya evaluated factors associated with LTFU in a cohort of 15-21-yearolds enrolled at a youth-dedicated clinic and a familyoriented clinic. Although there was a high proportion LTFU (57%), with 26% LTFU immediately, enrollment in a youth-specific clinic was not associated with reduced LTFU [76] .
By contrast, implementation of an adolescentfriendly clinic in Haiti was associated with improvements in the proportion of adolescents ages 13-19 enrolling in care, being assessed for ART eligibility, initiating ART, and a reduction in pre-ART attrition from 61 to 50% [9] . There was no impact, however, on long-term retention. In Kenya, implementation of AFS providing peer navigators, peer counseling, and psychosocial support at clinics and schools demonstrated substantial improvement in retention of AYALHIV ages 15-21 [77] . A large multicountry study evaluated factors associated with LTFU of AYALHIV ages 15-24, including availability of specific AFS [8] . Pre-ART LTFU was not associated with any of the evaluated AFS. Post-ART LTFU was lower at clinics providing condoms, or offering adolescent support groups. In Rwanda, where there was heterogeneity in the availability of adolescent peer educators, there was lower post-ART LTFU, though this was not significant because of small clinic size.
Although there are considerable limitations to the current literature, evidence from observational studies of the impact of AFS on retention is mixed [8,9,54,72,73 && ,75,76,78,79] . It is possible that provision of AFS may be insufficient to mitigate the causes of LTFU for many AYALHIV. In some contexts, there may be high initial attrition from HIV care prior to engagement with AFS [8, 53, 54, 76, 80, 81] . Furthermore, stigma, psychosocial issues, family, and community factors may be central to disengagement, and must be mitigated to realize optimal adolescent HIV outcomes [9,58,64 && ,75] . In adult studies, community-support models have shown promise in addressing stigma and other social factors, whereas facilitating care [73 && ,82 ]. An ongoing cluster randomized controlled trial in Zimbabwe will evaluate the impact of a multifaceted community-based program to improve ALHIV retention and adherence [83] .
Studies of interventions to improve adolescent retention in care are needed from multiple approaches [72] , particularly for pregnant adolescents and adolescents from key populations (Table 2) [84 && ,85-87] . To be most be impactful and relevant to youth, this research should evaluate adolescent needs in local contexts, undertaken through collaborative partnerships with AYALHIV themselves [60, 88] .
Sustaining ART adherence is critical to achieve virological suppression, prevent drug resistance, halt disease progression, and prevent transmission [48, 49, 89] . Evidence suggests that AYALHIV fail to achieve and maintain adequate adherence. In a study from South Africa, only 27% of 9-19-year olds achieved viral suppression, compared with 63% of 20-29-year olds [89] . In addition, adolescents had an increased risk of virological failure (adjusted hazard ratio¼2.06, P ¼ 0.002) [89] . Although systematic reviews have suggested that children, adolescents, and adults in LMIC have higher rates of ART adherence than those in HIC [90] [91] [92] , adherence is typically measured in LMIC by self or caregiver reports, which likely do not capture the full extent of nonadherence [92, 93] . Implementing other adherence measures for AYALHIV, including viral load, electronic dose, and therapeutic drug monitoring, hair drug concentrations, and novel approaches to pill counts such as looking for 'overadherence', all reveal the nonadherence and challenges such as treatment interruptions that compromise viral suppression [94] [95] [96] [97] [98] . The evidence for interventions to improve AYA adherence in LMIC remains extremely sparse [99] . A recent systematic review found only two effective interventions among high-quality studies: a phonebased counseling approach with adherence monitors and weekly individual and family counseling [99] . Only one of these studies was done in a LMIC (Thailand) [100] . Patient-oriented adaptations of healthcare delivery systems are considered a key requirement to improve ART adherence and retention in care for adults, as they can overcome structural barriers; allow more time and resources for adherence, disclosure, or mental health support; and lessen treatment fatigue and LTFU [101] . Evaluations of how such adaptations might improve AYALHIV outcomes are lacking. Another potential strategy for improving AYA adherence may come in the form of ART options with a higher genetic barrier to resistance and in once daily fixed dose combinations. Integrase inhibitors such as dolutegravir [102] have been effective in achieving high rates of viral suppression in other populations and long-acting injectable ART remains an attractive future goal. Access to newer ART classes is particularly pertinent given the extremely worryingly levels of transmitted drug resistance to both non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors emerging in infants from SSA for whom treatment options currently are extremely limited [103 && ].
CONCLUSION
AYALHIV are an acutely vulnerable group, with worse outcomes than adults at each stage of the care cascade, in all global settings. There is an urgent need to develop an evidence base for interventions to improve adolescent retention and adherence to ART. As a 'treat all' strategy is implemented globally, there is a need to identify interventions that are costeffective, scalable, and sustainable, to ensure adolescent retention in care and adherence to ART, to halt the rise in adolescent HIV-associated mortality, and ultimately to bring an end to the HIV/AIDS epidemic.
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